News

The Alzheimer’s Research UK Target Validation Pathfinder Grant Scheme & the Cambridge Drug Discovery Institute

http://www.alzheimersresearchuk.org/grants/target-validation-pathfinder-grant/

The Target Validation Pathfinder Grant scheme provides funds for small, translational research projects that show potential for collaboration with the ARUK Drug Discovery Alliance.

The ARUK Drug Discovery Alliance (DDA) is a network of Drug Discovery Institutes (DDIs) embedded within the Universities of Cambridge, Oxford and University College London. The DDA will take advantage of new science in neurodegenerative diseases that cause dementia from within the academic Institutions and elsewhere and rapidly translate this to novel drug discovery projects and/or novel biomarkers with clinical or diagnostic utility.

It is recognised that researchers may have promising data / projects which are too preliminary to progress to drug discovery. The Target Validation Pathfinder grant scheme (TVPG) is designed to support translational research that shows potential for collaboration with the ARUK Drug Discovery Alliance, but would benefit from funding for preliminary, early-stage target validation work or feasibility studies to establish the viability of an approach.

Duration: Up to 12 months.

Award: Up to £50,000 to cover staff salaries, equipment, animals, running costs, or any combinations of these.

Timing: There are four application rounds each year. The next deadlines are:

20/04/2016 (applicants will be notified of the decision by 8 July 2016) and 06/07/2016.

For more information please contact John Skidmore, CSO of the Alzheimer’s Research UK Cambridge Drug Discovery Institute or to find out about ARUK grant schemes or the application process please contact the ARUK Research Team research@alzheimersresearchuk.org or 0300 111 5555.